Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colistin-Rifampin vs Colistin for XDR A. Baumannii
NCT03622918Completed
- Sponsor
- Gangnam Severance Hospital
- Start
- Oct 2016
- Primary completion
- Sep 2017
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of rifampicin in Acinetobacter baumannii infection (2 arms), sponsored by Gangnam Severance Hospital. Primary endpoint: Microbiologic Response at 14 days. Started Oct 2016; status: completed.
02
Drugs
rifampicin
03
Conditions
Acinetobacter baumannii infection
Beyond the preview
Go deeper on NCT03622918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03622918.